Compare GLDD & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | GYRE |
|---|---|---|
| Founded | 1890 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.6M | 755.7M |
| IPO Year | 2006 | N/A |
| Metric | GLDD | GYRE |
|---|---|---|
| Price | $13.37 | $7.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 400.7K | 91.0K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.27 | N/A |
| EPS | ★ 1.19 | 0.04 |
| Revenue | ★ $834,599,000.00 | $107,265,000.00 |
| Revenue This Year | $12.71 | $11.59 |
| Revenue Next Year | $4.77 | $26.31 |
| P/E Ratio | ★ $11.22 | $185.48 |
| Revenue Growth | ★ 12.53 | 2.13 |
| 52 Week Low | $7.51 | $6.11 |
| 52 Week High | $14.02 | $14.42 |
| Indicator | GLDD | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 42.05 |
| Support Level | $13.28 | $7.05 |
| Resistance Level | $13.60 | $7.39 |
| Average True Range (ATR) | 0.36 | 0.35 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 43.10 | 22.61 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.